Literature DB >> 19715640

[Controversial issues in congenital nevi].

S Paradela1, R Fernández-Torres, E Fonseca.   

Abstract

Congenital melanocytic nevi are very common lesions that nevertheless pose many controversial questions. A systematic review of the literature suggests that the risk of developing melanoma on giant congenital melanocytic nevi (GCMN) is lower than previously thought given that, in the most recent series of GCMN, only 2 % of patients developed melanoma and most did so before the age of 5 years. Therefore,prophylactic surgery should be considered on an individual basis according to the degree of clinical suspicion of melanoma and the esthetic and functional consequences.In extensive reviews of series of biopsies of melanoma, small congenital melanocytic nevi have been associated with 7 % to 8 % of cases. Many authors believe that these might represent a significant risk of malignant conversion from 10 years onwards and so recommend regular control visits during infancy and prophylactic exeresis in puberty.

Entities:  

Mesh:

Year:  2009        PMID: 19715640

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  2 in total

1.  Retrospective analysis of melanocytic lesions in children at the National Cancer Institute-RJ.

Authors:  Lislaine Bomm; Ricardo Vianna de Carvalho; Fernanda Ferreira da Silva Lima; Lidicie Natalia Braga de Oliveira; Fernanda Tolstoy; Dolival Lobão
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

2.  Brazilian guidelines for diagnosis, treatment and follow-up of primary cutaneous melanoma - Part II.

Authors:  Luiz Guilherme Martins Castro; Renato Marchiori Bakos; João Pedreira Duprat Neto; Flávia Vasques Bittencourt; Thais Helena Bello Di Giacomo; Sérgio Schrader Serpa; Maria Cristina de Lorenzo Messina; Walter Refkalefsky Loureiro; Ricardo Silvestre e Silva Macarenco; Hamilton Ometto Stolf; Gabriel Gontijo
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.